Thrombosis research
-
Thrombosis research · Jan 2015
Multicenter StudyTinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
After 6months, little is known about the optimal anticoagulant strategy for an acute episode of VTE in cancer patients. ⋯ The risk of recurrent VTE was mainly related to early discontinuation of anticoagulation in patients considered at low risk of recurrence (after surgery). When the anticoagulation was stopped before the sixth month, the risk was eight fold higher. After 6month, the risks of recurrent VTE, major bleeding and death were similar in patients with either VKA or tinzaparin when patients were treated according to the guidelines.